FIELD: medicine; pharmaceutics.
SUBSTANCE: present description provides a combination therapy useful for treating hepatocellular carcinoma. Combination includes an FGFR4 inhibitor and CDK 4/6 inhibitor.
EFFECT: this combination provides enhanced anticancer effect.
23 cl, 3 ex, 8 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPIES FOR TREATMENT OF HEPATOCELLULAR CARCINOMA | 2019 |
|
RU2787993C2 |
| COMBINATION THERAPY FOR TREATMENT OF MAMMARY GLAND CANCER | 2018 |
|
RU2764724C2 |
| CRYSTALLINE FGFR4 INHIBITOR AND ITS APPLICATION | 2016 |
|
RU2763328C2 |
| COMBINATIONS OF TGFβ INHIBITORS AND CDK INHIBITORS FOR TREATMENT OF BREAST CANCER | 2019 |
|
RU2784852C2 |
| FGFR4 INHIBITORS | 2014 |
|
RU2715708C2 |
| METHODS FOR TREATING CANCER | 2016 |
|
RU2747228C2 |
| METHODS OF TREATING CDK4/6 INHIBITOR-RESISTANT CANCER | 2019 |
|
RU2820478C2 |
| METHODS OF TREATING AR+ BREAST CANCER | 2017 |
|
RU2769527C2 |
| PHARMACEUTICAL COMBINATION CONTAINING TNO155 AND RIBOCICLIB | 2020 |
|
RU2813111C2 |
| COMPLEX THERAPY FOR CANCER TREATMENT | 2018 |
|
RU2810487C2 |
